,0,1
0,listing rules,9.0
1,consolidated statements,8.833333333333334
2,proceeding investigation,8.833333333333334
3,donepezil hydrochloride capsule,8.8
4,scholes model,8.777777777777779
5,secondary endpoint,8.75
6,onset seizures,8.75
7,release version,8.74645390070922
8,release version,8.74645390070922
9,merz pharma gmbh,8.666666666666666
10,merz pharmaceuticals,8.666666666666666
11,onset seizure,8.625
12,generic version,8.55895390070922
13,movement disorder specialist,8.545833333333334
14,significant improvement,8.518072289156626
15,compensation contractor,8.490322580645161
16,neurologic disorder,8.479166666666666
17,compensation stock compensation,8.417763157894736
18,stock unit,8.417763157894736
19,consolidated statement,8.369047619047619
20,shelf registration statement,8.369047619047619
21,accounting policy,8.368421052631579
22,accounting standards,8.368421052631579
23,record significant additional,8.360177552314521
24,reimbursed expense,8.304347826086957
25,net income,8.291634210936282
26,outcome measure,8.285714285714285
27,synchronous therapy,8.25
28,generic entry,8.229166666666666
29,severe dementia,8.204608294930875
30,court decision,8.2
31,cash flows,8.191666666666666
32,quoted price,8.18560606060606
33,line basis,8.181818181818182
34,phase trial,8.167919799498748
35,technical corrections,8.142857142857142
36,dose phase,8.142857142857142
37,commercial capability,8.126984126984127
38,single digit,8.125
39,clinical trial,8.091986723565672
40,clinical trial,8.091986723565672
41,trial accruals,8.091986723565672
42,preferred stock,8.084429824561402
43,permission,8.08108108108108
44,eitf meeting,8.06024096385542
45,subsidiary summary,8.0
46,ucb sa nv,8.0
47,delivery,7.988700564971751
48,credit risk,7.977272727272727
49,phase week proof,7.9714285714285715
50,cash cash,7.959090909090909
51,cash flow,7.953571428571429
52,monetary relief,7.945054945054945
53,financial contribution,7.904626911005366
54,fiscal year,7.817733990147783
55,month,7.816216216216215
56,generic version,7.804855540053483
57,vesting period,7.801204819277109
58,cmos expense,7.794670406732118
59,related expense,7.794670406732118
60,credit loss,7.787513691128148
61,equity offering,7.784782608695652
62,note thereto,7.781989247311827
63,financial statement,7.7556022408963585
64,orphan drug exclusivity,7.743303571428571
65,net loss,7.7396302768325205
66,additional fund,7.726720647773279
67,sale agent,7.699507389162561
68,liquid investment,7.695652173913043
69,cashless exercise,7.673076923076923
70,valuation technique,7.666666666666666
71,clinical trial,7.663415294994242
72,substantial doubt,7.657894736842105
73,wa primarily related,7.6468677898219495
74,namenda xr,7.639175257731959
75,net proceeds,7.622466236054022
76,asu rescission,7.616541353383459
77,based compensation,7.605797345928925
78,balance sheet arrangement,7.599832915622389
79,common stock,7.599581339712918
80,average number,7.5993589743589745
81,market price,7.598174366616989
82,commercial organization,7.59804567413263
83,fasb ha issued,7.59716617343736
84,net interest,7.595982037023239
85,interest income,7.595982037023239
86,commercial activity,7.580555555555556
87,sustained profitability,7.5777777777777775
88,wa primarily due,7.577597840755736
89,salary benefit,7.573476702508961
90,market data,7.569943451190952
91,expense allocation,7.554347826086957
92,month,7.526457180071637
93,decrease,7.51359649122807
94,investigator site,7.495495495495495
95,symptomatic relief,7.492063492063492
96,equity incentive plan,7.490243902439024
97,united states,7.479166666666667
98,component,7.467105263157895
99,andadministrative net,7.463703038467296
100,net cash,7.454389312977099
101,equity instrument,7.43531746031746
102,public offering,7.434782608695652
103,salary,7.433380084151473
104,net proceeds,7.426055979643765
105,net income,7.423213158304703
106,fasb issued asu,7.417989417989418
107,common stock,7.414396154527733
108,fda ha designated,7.4031149793861655
109,long term,7.3996003996004
110,term debt,7.3996003996004
111,capital stock,7.399244639376218
112,agreement,7.392544802867383
113,objective expectation,7.390243902439025
114,significant decrease,7.384738955823293
115,anda filer,7.380050505050505
116,automatically net exercised,7.3793893129771
117,generic namenda,7.368341924398626
118,underwriting discount,7.358108108108108
119,increased expense,7.357170406732118
120,issuance options,7.345000000000001
121,year beginning,7.34476101717481
122,footnote disclosure,7.336476426799008
123,product candidate,7.333852842260684
124,specific expense,7.332736104475236
125,month,7.316609917003618
126,quoted price,7.314638318670577
127,public offering,7.309782608695652
128,stock compensation plan,7.308007060333761
129,induced dyskinesia,7.296703296703296
130,similar security,7.294962812711291
131,generic version,7.289723131478452
132,clinical research,7.286455947472897
133,fda approval,7.281081081081081
134,approval,7.281081081081081
135,licensing arrangement,7.280701754385965
136,cash proceeds,7.2716666666666665
137,increased investment,7.258152173913043
138,effort,7.25
139,milestone payment,7.249582289055974
140,development expense,7.2394127611518915
141,business adamas pharmaceuticals,7.238636363636363
142,external cost,7.2375753278979085
143,anda filer,7.236111111111112
144,payment,7.23063492063492
145,market price,7.223174366616989
146,party data provider,7.213204373423045
147,specific basis,7.210206460206461
148,unobservable input,7.203659123736157
149,double digit,7.2
150,leaseback transaction,7.199507389162561
151,consulting fee,7.197994987468672
152,stock option,7.181808101714961
153,stock split,7.167763157894736
154,quoted pricing,7.166666666666667
155,beginning,7.166202284758986
156,clinical study,7.162162162162161
157,account,7.156989247311827
158,plan,7.152743902439024
159,financial statement,7.1306022408963585
160,ease lid,7.12199036918138
161,sale agent,7.116174055829228
162,judgment,7.108108108108108
163,based award,7.105797345928925
164,annual period,7.105552645364065
165,comprehensive loss,7.1019076305220885
166,advance payment,7.087301587301587
167,stage program,7.085470085470085
168,tax asset,7.0851449275362315
169,cash payment,7.078968253968254
170,significant loss,7.078313253012047
171,increased activity,7.077822580645162
172,dilutive security,7.0771756978653535
173,payment,7.073455433455434
174,clinical personnel,7.0669240669240665
175,common stock,7.059898800030378
176,increase wa offset,7.056020733652312
177,sales agreement,7.050370370370371
178,fiscal period,7.04251756058985
179,market input,7.034814219301618
180,backed loan,7.028505897771953
181,common stock,7.016248006379584
182,march license agreements,7.01229575837597
183,development expense,7.011342585713296
184,united states,7.006193693693694
185,operating loss,6.994979919678714
186,stock warrant,6.955397566496887
187,percentage revenue revenue,6.947222222222223
188,term success,6.945054945054945
189,preclinical testing,6.935064935064935
190,tiered royalty,6.933785400877543
191,significant increase,6.927163198247535
192,company,6.924750337381916
193,common stock,6.921615238018003
194,observable input,6.917944838021873
195,stock option,6.901808101714963
196,espp automatically increased,6.898863636363637
197,related note,6.897373862696442
198,drug application nda,6.897365196078431
199,early adoption,6.894444444444445
200,lease commitments,6.893162393162393
201,financial statement,6.8846344989608745
202,revenue recognition,6.883928571428571
203,filed lawsuit,6.864035087719298
204,period,6.86144578313253
205,ten year,6.853448275862069
206,research organization,6.851673338777244
207,tolerability issue,6.842105263157895
208,approval,6.830952380952381
209,attorney fee cost,6.8262001156738
210,selling price,6.8238446336272425
211,net cash,6.812232450232001
212,significant research,6.809032741134027
213,stock award plan,6.808007060333761
214,trial vendor,6.806272437851385
215,june license agreements,6.802448495307949
216,development expense,6.8019127611518915
217,noncurrent amount,6.792207792207792
218,product revenue,6.7890469061876235
219,maturity date range,6.784172661870503
220,concept study,6.761904761904762
221,clinical trial,6.758653390232338
222,research institution,6.755246166263116
223,product candidate,6.750519508927351
224,service fee,6.75
225,liability income tax,6.747448979591836
226,sale security,6.74692118226601
227,year,6.743448275862069
228,mandatory prepayment,6.7407407407407405
229,development expense,6.7394127611518915
230,partial exercise,6.738461538461539
231,issuance shares,6.730882352941176
232,significant spending,6.725619458967947
233,lid,6.718481597251556
234,lid trial,6.718481597251556
235,xr royalty,6.7033954412181975
236,price,6.695810142238713
237,common share,6.69298927193664
238,development expense,6.683857205596336
239,drug administration,6.6815275096525095
240,element arrangement,6.679197994987469
241,states court,6.679166666666667
242,financial information,6.670208468002586
243,interest income,6.66659272404614
244,forest,6.661190476190476
245,revenue,6.659764957264958
246,revenue,6.659764957264958
247,revenue,6.659764957264958
248,period,6.6515985200645105
249,clinical trial,6.64254852131848
250,xr litigation,6.639175257731959
251,product candidate expense,6.6382006683476416
252,subjective assumption,6.635719347980155
253,annual period,6.632579672391092
254,effective date,6.6290002480774
255,vimpat tablet,6.611111111111111
256,sclerosis patient,6.607956600361663
257,contractual obligation,6.605882352941176
258,recurring adjustment,6.583333333333333
259,significant loss,6.578313253012047
260,short term,6.567795908910367
261,asserted patent,6.557791537667699
262,wa declared effective,6.545328839339729
263,net cash,6.537722646310432
264,early adoption,6.5344444444444445
265,corporate debt,6.531468531468532
266,million net,6.526448136506511
267,relevant patent,6.526292335115864
268,development revenue,6.525342712842713
269,common stock,6.5138670539986325
270,common stock,6.502807146164532
271,district court,6.502422723475355
272,treasury note,6.491666666666666
273,net sale,6.484779055080837
274,product revenue recognition,6.483491350632069
275,pharmaceutical company,6.475042735042734
276,additional share,6.452747252747253
277,management judgment,6.447608968693306
278,product candidate,6.439735195201861
279,related expense,6.4375275495892605
280,development activity,6.4373376623376615
281,future period,6.434114199245312
282,fiscal year,6.424876847290641
283,year item management,6.424876847290641
284,anda filer,6.423325722983257
285,contract manufacturing organization,6.412675018422991
286,stock option,6.412577332484193
287,reporting period,6.410516560167797
288,activity level,6.390853658536586
289,based award,6.384390463337832
290,study research,6.381694042710992
291,license agreement,6.381304043769798
292,commercial activity,6.364869281045752
293,extension,6.359625668449198
294,short term,6.357948645842347
295,subtopic disclosure,6.346153846153847
296,million primarily related,6.339643847613487
297,product sale,6.314943184239074
298,purchase commitments,6.299906629318394
299,actual result,6.288461538461538
300,year revenue,6.27705938697318
301,financial result,6.271170006464124
302,public offering,6.268115942028985
303,external cost,6.247252747252747
304,development expense,6.2394127611518915
305,drug,6.236202485380117
306,public offering,6.234782608695652
307,memantine product,6.226546906187624
308,partial exercise,6.223076923076924
309,exercised option,6.2084893882646695
310,net loss,6.204336159185462
311,contract research organization,6.203635470400393
312,analysis expense,6.194670406732118
313,received million related,6.181695129664769
314,company interest,6.179390561129692
315,actual service,6.171052631578947
316,government contract research,6.138418079096045
317,product candidate,6.1181665677508805
318,short term,6.115398082309847
319,december wa derived,6.099429824561404
320,service,6.087719298245614
321,additional share,6.083916083916083
322,business entity,6.083333333333333
323,wa million compared,6.069969040247678
324,actual result,6.038461538461538
325,development expense research,6.030373213129293
326,exchange commission sec,6.02051282051282
327,addition expense,6.014182601854069
328,contract,5.990314769975788
329,united states,5.942934782608696
330,item management,5.929271708683473
331,contingent element,5.928774928774929
332,warrant wa determined,5.91562483922416
333,states forest,5.913690476190476
334,claim litigation,5.9135746606334845
335,public offering,5.899488491048594
336,period management,5.885791285442521
337,milestone subject,5.857142857142858
338,revenue recognition standard,5.846688034188034
339,company,5.817439048406791
340,reported revenue,5.805190058479532
341,company,5.733406593406594
342,management,5.696428571428571
343,allergan,5.669921962095875
344,forest,5.6406776556776554
345,enrollment level,5.637302322390313
346,ii share,5.609083548030917
347,product commercialization,5.606246154307925
348,enforcement action,5.584040008697543
349,completion date,5.581375459073301
350,degree reimbursement,5.56712962962963
351,generic version,5.55895390070922
352,generic commitments,5.506944444444445
353,share amount,5.488564067511436
354,liability level input,5.45068460584088
355,cost,5.4320353559484
356,allergan license agreement,5.318045132684799
357,repayment term,5.317147968310759
358,net income,5.291634210936283
359,income net,5.291634210936283
360,stock,5.232577972709551
361,financial statements,5.219887955182073
362,net cash,5.204389312977099
363,net proceeds,5.199389312977099
364,quoted price,5.1856060606060606
365,liability level asset,5.169536001038804
366,phase phase,5.142857142857143
367,commercial capability,5.1269841269841265
368,multiple sclerosis,5.114285714285714
369,clinical trial,5.091986723565671
370,preferred stock,5.084429824561403
371,clinical program,5.059598059598059
372,specific program,5.028388278388279
373,incur significant,5.018072289156626
374,average price,4.977272727272727
375,ipo,4.9726410621147465
376,agreement allergan,4.9712534960589885
377,corporate debt,4.954545454545455
378,cash flow,4.953571428571428
379,agreement forest,4.9420091896407685
380,income expense,4.91659272404614
381,anda filer,4.902777777777778
382,early adoption,4.894444444444445
383,increased expense,4.866847826086957
384,ads,4.857368006304176
385,transaction price,4.852272727272727
386,drug application,4.838541666666666
387,debt instrument,4.829545454545455
388,fiscal year,4.817733990147783
389,primarily due,4.805668016194332
390,profitability,4.8
391,treasury note,4.791666666666666
392,cash adjustment,4.775
393,financial instrument,4.76155462184874
394,financial statement,4.7556022408963585
395,anda,4.740384615384615
396,voluntary movement,4.733333333333333
397,involuntary movement,4.733333333333333
398,disease indication,4.7303030303030305
399,anti dilutive,4.73015873015873
400,commercial revenue,4.729166666666666
401,generic warrants,4.729166666666666
402,credit losses,4.727272727272727
403,market,4.710187353629976
404,final judgment,4.68705547652916
405,basis,4.681818181818182
406,net maturity,4.679389312977099
407,milestone payment,4.670634920634921
408,phase study,4.666666666666667
409,deferred taxes,4.666666666666666
410,substantial doubt,4.657894736842105
411,incur substantial,4.657894736842105
412,namenda xr,4.639175257731959
413,million sale,4.627981387457532
414,significant judgment,4.626180397264735
415,average rent,4.625
416,interest expense,4.608695652173913
417,common stock,4.599581339712918
418,million sale,4.598737081039312
419,clinical study,4.59073359073359
420,revenue,4.590277777777778
421,fasb approved,4.588399720475192
422,upfront payment,4.587301587301587
423,future licensing,4.579566563467493
424,related fee,4.569269949066214
425,debt discount,4.562653562653562
426,product,4.5598802395209574
427,embedded derivative,4.5576923076923075
428,commercial viability,4.555555555555555
429,administrative expense,4.554347826086957
430,additional share,4.538461538461538
431,price,4.537055335968379
432,payment term,4.532356532356532
433,interest,4.531014492753624
434,activity,4.525
435,early stage,4.521367521367521
436,gross proceeds,4.52
437,significant competition,4.518072289156626
438,related activity,4.515322580645162
439,short term,4.507554945054945
440,reconciling item,4.5
441,federal circuit,4.5
442,wa terminated,4.499202551834131
443,development program,4.499167499167499
444,clinical pipeline,4.495495495495495
445,clinical work,4.495495495495495
446,expense,4.489130434782609
447,option,4.484044943820225
448,united states,4.479166666666667
449,twelve month,4.466216216216216
450,month,4.466216216216216
451,thper month,4.466216216216216
452,plan,4.452743902439025
453,operating activity,4.441666666666666
454,price,4.4392292490118574
455,licensing arrangement,4.43859649122807
456,comprehensive loss,4.4352409638554215
457,public offering,4.434782608695652
458,market offering,4.430684248039915
459,clinical development,4.430560430560431
460,revenue recognition,4.423611111111111
461,certification,4.416666666666666
462,substantial risk,4.407894736842105
463,therapy,4.403846153846153
464,common stockholder,4.396103896103896
465,financial instruments,4.38655462184874
466,consisted primarily,4.384615384615385
467,net sale,4.378896702139661
468,statement factors,4.369047619047619
469,fee,4.364661654135338
470,preferred share,4.363022941970311
471,significant component,4.360177552314521
472,underwriting discount,4.358108108108108
473,closing price,4.352272727272727
474,government contract,4.347457627118644
475,discount,4.3347747747747745
476,product candidate,4.333852842260685
477,effort,4.333333333333334
478,payment,4.328042328042328
479,increased cost,4.309752747252747
480,investment income,4.307897071872227
481,additional million,4.306811145510836
482,share data,4.30611237286462
483,prepaid expense,4.304347826086957
484,expense,4.304347826086957
485,contra expense,4.304347826086957
486,accompanying note,4.291666666666666
487,business,4.291666666666666
488,clinical research,4.286455947472897
489,commercial launch,4.286324786324786
490,generally cancelable,4.285714285714286
491,current accounting,4.285087719298246
492,entry date,4.284172661870503
493,approval,4.281081081081082
494,exists ii,4.272727272727273
495,issue,4.272727272727273
496,market activity,4.270901639344262
497,adjustment,4.25
498,institution maturity,4.25
499,risk,4.25
500,numerous risk,4.25
501,product,4.247914427555147
502,actual cost,4.247252747252747
503,market pricing,4.245901639344263
504,market acceptance,4.245901639344263
505,development expense,4.2394127611518915
506,royalty revenue,4.237831294597349
507,related cost,4.2375753278979085
508,wa million,4.2366357069143445
509,entity,4.2214912280701755
510,share proceeds,4.216356275303644
511,actual probability,4.214285714285714
512,amount,4.213260423786739
513,similar asset,4.2101449275362315
514,pharmacokinetic profile,4.201923076923077
515,emeryville california,4.2
516,regulatory approval,4.2
517,material contingencies,4.2
518,espp,4.198863636363637
519,investment,4.195652173913043
520,related material,4.190322580645161
521,estimated indemnification,4.181818181818182
522,stock option,4.181808101714962
523,financial asset,4.180032882718304
524,vendor,4.178571428571429
525,revenue,4.173611111111111
526,revenue,4.173611111111111
527,topic revenue,4.173611111111111
528,drug applications,4.171875
529,drug,4.171875
530,allergan,4.169650468883206
531,vary depending,4.1688311688311686
532,office space,4.166666666666666
533,capital requirement,4.166666666666666
534,related service,4.161375212224108
535,substantial majority,4.157894736842105
536,related good,4.156989247311828
537,share,4.156673735621104
538,interim period,4.147358665430954
539,independently validated,4.142857142857142
540,dyskinesia abnormality,4.142857142857142
541,forest,4.140406162464986
542,difference,4.129032258064516
543,mid teen,4.125
544,prepayment,4.125
545,lid,4.121990369181381
546,subjective assumption,4.117647058823529
547,early exercise,4.117521367521368
548,automatically increase,4.109090909090909
549,judgment,4.108108108108108
550,thousand contingencies,4.107843137254902
551,drug development,4.106939935064935
552,date,4.106206560175588
553,foreseeable future,4.105882352941176
554,year deferral,4.103448275862069
555,year,4.103448275862069
556,prior year,4.103448275862069
557,active market,4.1030444964871196
558,orphan disease,4.101731601731602
559,purchase common,4.096103896103896
560,study,4.095238095238095
561,substantive milestone,4.083333333333334
562,regulatory milestone,4.083333333333334
563,amount,4.077922077922078
564,safety profile,4.076923076923077
565,revenue agreement,4.075833333333334
566,investment instrument,4.070652173913043
567,patent,4.070387129210658
568,classified statement,4.069047619047619
569,period,4.06436271401395
570,exclusively licensed,4.064327485380117
571,enforcement action,4.063492063492063
572,increasing loss,4.0602409638554215
573,incurred loss,4.0602409638554215
574,commercialized product,4.0598802395209574
575,sales agreement,4.050370370370371
576,relevant patent,4.049019607843137
577,namzaric beginning,4.047574972232507
578,date,4.047330556607346
579,wa amortized,4.044657097288677
580,exclusive license,4.042963885429639
581,district court,4.042105263157895
582,issuance,4.041666666666666
583,research institution,4.040960451977401
584,daily administration,4.0396825396825395
585,actual result,4.038461538461538
586,financial condition,4.036554621848739
587,license milestone,4.0353881278538815
588,operating lease,4.032051282051282
589,lid,4.027834525025536
590,lacosamide therapy,4.027777777777778
591,exercise price,4.02534965034965
592,factor,4.0227272727272725
593,made pursuant,4.021929824561403
594,amount,4.018874458874459
595,operations,4.0
596,necessarily indicative,4.0
597,historical experience,4.0
598,persuasive evidence,4.0
599,defined objective,4.0
600,relate solely,4.0
601,performed basic,4.0
602,periodic revaluation,4.0
603,core principle,4.0
604,actively traded,4.0
605,shown separately,4.0
606,rent,4.0
607,restated certificate,4.0
608,restated bylaw,4.0
609,submitted abbreviated,4.0
610,invalid unenforceable,4.0
611,issue prior,4.0
612,markman hearing,4.0
613,cosmetic act,4.0
614,substantively exercised,4.0
615,discretion issue,4.0
616,unvested rsu,4.0
617,statistical compilation,4.0
618,regulatory requirement,4.0
619,consistently classify,4.0
620,audit committee,4.0
621,staff announcements,4.0
622,practical expedients,4.0
623,postural instability,4.0
624,preclinical work,4.0
625,vii iv,4.0
626,small degree,4.0
627,dos,4.0
628,reported level,3.997432605905007
629,product development,3.994945174585893
630,allergan,3.9907951429690565
631,platform,3.988034188034188
632,stockholder,3.987870619946092
633,company,3.9861538461538464
634,estimated amount,3.974025974025974
635,arrangement,3.9649122807017543
636,arrangement events,3.9649122807017543
637,forest beginning,3.9615508365508365
638,principal amount,3.9588744588744587
639,entity,3.958333333333333
640,entity satisfies,3.958333333333333
641,million related,3.9550284629981025
642,activity,3.948076923076923
643,disease,3.946969696969697
644,approved drug,3.9454599056603774
645,acceptable term,3.9450549450549453
646,million including,3.941978609625668
647,human therapeutic,3.9411764705882355
648,total number,3.9410256410256412
649,level input,3.940480524208227
650,pricing information,3.9375
651,lesser degree,3.9375
652,development funding,3.9350649350649354
653,development project,3.9350649350649354
654,development selection,3.9350649350649354
655,continued development,3.9350649350649354
656,development strategy,3.9350649350649354
657,royalty,3.933785400877543
658,walking impairment,3.9305555555555554
659,severe alzheimer,3.924812030075188
660,amount,3.9237867395762134
661,identical security,3.9224137931034484
662,license arrangement,3.9169670752223023
663,current status,3.916666666666667
664,lesser number,3.9118589743589745
665,fund activity,3.9096153846153845
666,future period,3.9070871722182847
667,effective march,3.9050685500623183
668,settlement agreement,3.902222222222222
669,distribution agreement,3.902222222222222
670,partnership agreement,3.902222222222222
671,premium,3.901098901098901
672,service,3.897719298245614
673,achieved based,3.893916540975365
674,result price,3.890734265734266
675,inducement plan,3.8902439024390243
676,raised million,3.8877828054298638
677,drug response,3.8861607142857144
678,generated primarily,3.8846153846153846
679,lid,3.8838951310861427
680,unrealized gain,3.8823529411764706
681,gain realized,3.8823529411764706
682,gain,3.8823529411764706
683,million pursuant,3.8813725490196074
684,ms ads,3.875886524822695
685,pharmaceutical company,3.8750427350427348
686,business strategy,3.875
687,markman ruling,3.875
688,lid ha,3.8725956960578936
689,sale security,3.87192118226601
690,exchange commission,3.8666666666666667
691,loan agreement,3.8665079365079364
692,modest level,3.8658536585365857
693,active ingredient,3.857142857142857
694,license agreement,3.8542770167427705
695,aggregate offering,3.8514492753623193
696,actual timing,3.85
697,contract determinations,3.847457627118644
698,host contract,3.847457627118644
699,approximately million,3.8470588235294114
700,largest component,3.8421052631578947
701,transition method,3.833333333333333
702,employee,3.830891330891331
703,development plan,3.8253088375039592
704,management belief,3.821428571428571
705,pay royalty,3.8142201834862384
706,intellectual property,3.8095238095238093
707,company,3.808187744458931
708,claim,3.8076923076923075
709,period,3.8012048192771086
710,ads,3.7969391564016424
711,underlying asset,3.7934782608695654
712,contract term,3.792512572173589
713,amount,3.792207792207792
714,party,3.791482463896257
715,research,3.7909604519774014
716,subcontractor research,3.7909604519774014
717,incurred research,3.7909604519774014
718,sec liquidity,3.79020979020979
719,relevant assumption,3.784313725490196
720,general indemnification,3.784313725490196
721,earliest date,3.7841726618705036
722,vimpat lacosamide,3.7777777777777777
723,expire beginning,3.777027027027027
724,nih grant,3.7727272727272725
725,patient enrollment,3.771448663853727
726,major symptom,3.769230769230769
727,andas,3.769230769230769
728,annual report,3.7686335403726705
729,unvested option,3.764044943820225
730,loan amount,3.7564935064935066
731,term,3.7527472527472527
732,indirect cost,3.7472527472527473
733,integral part,3.7407407407407405
734,patent subject,3.7394957983193278
735,commercialization effort,3.736842105263158
736,public company,3.7361538461538464
737,future issuance,3.7308823529411765
738,consideration,3.7266666666666666
739,development research,3.7260253870423363
740,including january,3.7228867623604467
741,result common,3.72027972027972
742,reasonable relative,3.717948717948718
743,borrowed million,3.7147058823529413
744,quarterly report,3.7142857142857144
745,company,3.712820512820513
746,allergan market,3.709669755286291
747,company,3.7083760683760687
748,performance requirement,3.7058823529411766
749,milestones,3.7058823529411766
750,counterparty performance,3.7058823529411766
751,prior performance,3.7058823529411766
752,achieved prior,3.7058823529411766
753,estimate including,3.700802139037433
754,cantor fitzgerald,3.7
755,sale force,3.6995073891625614
756,sale representative,3.6995073891625614
757,sale volume,3.6995073891625614
758,fractional share,3.6963562753036436
759,issue share,3.6963562753036436
760,unvested share,3.6963562753036436
761,underlying investment,3.6956521739130435
762,received million,3.691372549019608
763,development cost,3.6823176823176826
764,forest market,3.680425448868072
765,expense,3.6793478260869565
766,active management,3.678571428571429
767,agreement grant,3.674949494949495
768,revenue,3.673611111111111
769,promised good,3.666666666666667
770,table,3.666666666666667
771,table,3.666666666666667
772,occur prior,3.666666666666667
773,principal source,3.6666666666666665
774,lid,3.6659464131374246
775,research,3.648103309120258
776,successfully develop,3.6470588235294117
777,work,3.645161290322581
778,relative fair,3.644230769230769
779,employee deposit,3.642857142857143
780,remaining quarter,3.6410256410256414
781,liability,3.639236339697169
782,million revenue,3.638316993464052
783,action,3.634920634920635
784,complete reimbursement,3.6296296296296298
785,effective date,3.6290002480774
786,amantadine therapy,3.625
787,leveraged lease,3.6153846153846154
788,prepayment premium,3.6153846153846154
789,purchase share,3.6106419895893582
790,development service,3.6061175666438823
791,future expenditure,3.6058823529411765
792,payments,3.605263157894737
793,party evidence,3.603448275862069
794,sale agreement,3.601729611384784
795,share,3.5995820817552566
796,operation,3.596153846153846
797,total issuance,3.591666666666667
798,supporting prosecution,3.583333333333333
799,fee,3.5789473684210527
800,alternative future,3.560427807486631
801,disease activity,3.55530303030303
802,full term,3.552197802197802
803,recognize revenue,3.548611111111111
804,potential commercialization,3.5463659147869673
805,measure fair,3.54532967032967
806,identical asset,3.5434782608695654
807,safety result,3.5384615384615383
808,contingent asset,3.534219001610306
809,terminated earlier,3.5272727272727273
810,product,3.5236483554629867
811,retroactively adjusted,3.5
812,collectability,3.5
813,fixed nature,3.5
814,substantive uncertainty,3.5
815,incorporation authorizes,3.5
816,accumulated deficit,3.5
817,readily apparent,3.5
818,access,3.5
819,regulatory change,3.5
820,product forest,3.4944040490447676
821,company belief,3.4861538461538464
822,company,3.4861538461538464
823,company,3.4861538461538464
824,company,3.4861538461538464
825,company,3.4861538461538464
826,permit company,3.4861538461538464
827,company,3.4861538461538464
828,company,3.4861538461538464
829,company,3.4861538461538464
830,company,3.4861538461538464
831,company,3.4861538461538464
832,occurrence subject,3.482142857142857
833,includes finding,3.4814814814814814
834,portfolio,3.4814814814814814
835,totaled million,3.4647058823529413
836,allergan plc,3.4637681159420293
837,director,3.4634146341463414
838,director,3.4634146341463414
839,successfully manufacture,3.4545454545454546
840,commercially manufacturing,3.4545454545454546
841,bedtime,3.448717948717949
842,estimated fair,3.4414335664335662
843,sell namzaric,3.4237737516570927
844,food drug,3.421875
845,implementing conducting,3.416666666666667
846,mg day,3.416666666666667
847,lease period,3.4165894346617236
848,research,3.4159604519774014
849,adversely affected,3.4117647058823533
850,issuance date,3.4091726618705036
851,increase annually,3.409090909090909
852,increase significantly,3.409090909090909
853,commercialization committee,3.4035087719298245
854,measurement date,3.399557277255119
855,epilepsy,3.393162393162393
856,require fair,3.3846153846153846
857,adequate fund,3.3846153846153846
858,forest,3.381892230576441
859,company plan,3.3763977485928702
860,time issue,3.375
861,time consuming,3.375
862,volatility,3.3720930232558137
863,approach result,3.371794871794872
864,company fund,3.3707692307692305
865,sec guidance,3.3669609079445144
866,underwriter option,3.364044943820225
867,product collaboration,3.362910542551261
868,completion cost,3.3626373626373627
869,predict subject,3.357142857142857
870,liability disclosure,3.356357927786499
871,loss,3.3380187416331992
872,full launch,3.337912087912088
873,delay,3.333333333333333
874,addition judgment,3.3276203032300593
875,investment type,3.3206521739130435
876,director subject,3.3205574912891986
877,expected term,3.317147968310759
878,sale,3.3047705470572986
879,million compared,3.2980392156862743
880,recognized based,3.2967298402081013
881,research,3.2909604519774014
882,namzaric andas,3.289778714436249
883,facility,3.2857142857142856
884,milestone,3.2756410256410255
885,medicine,3.2735849056603774
886,collaboration arrangement,3.267942583732057
887,expires april,3.263157894736842
888,dividend,3.261904761904762
889,asc fair,3.2596153846153846
890,share,3.241810820758189
891,financing lease,3.2403846153846154
892,director,3.236999539806719
893,company,3.2361538461538464
894,revised guidance,3.2131147540983607
895,guidance simplifies,3.2131147540983607
896,operation comparison,3.2115384615384617
897,performance obligation,3.2058823529411766
898,company,3.2004395604395603
899,material change,3.2
900,share attributable,3.1963562753036436
901,investment exposure,3.1956521739130435
902,parkinson,3.1951219512195124
903,increase general,3.193404634581105
904,rendered iii,3.1875
905,update prospectively,3.1875
906,namzaric granting,3.1872146118721463
907,defendant andas,3.1809954751131224
908,approved commercialization,3.177093677590202
909,time period,3.1762048192771086
910,form partnership,3.166666666666667
911,dosage form,3.166666666666667
912,expiration date,3.1591726618705036
913,medicine,3.1470588235294117
914,company,3.131315136476427
915,promotional support,3.105263157894737
916,january subject,3.102756892230577
917,anticipate general,3.096813725490196
918,research,3.0850780990362248
919,disease lid,3.080864828055839
920,estimation hierarchy,3.0769230769230766
921,exclusivities,3.0625
922,epilepsy lacosamide,3.0555555555555554
923,disclosure,3.046153846153846
924,july warrant,3.0376344086021505
925,amortization period,3.023427041499331
926,bedtime ads,2.9912711402073104
927,company,2.9861538461538464
928,company limit,2.9861538461538464
929,people,2.9831932773109244
930,expect general,2.9766214177978885
931,lease,2.9764957264957266
932,daily life,2.974747474747475
933,estimate,2.9642701525054465
934,company,2.9406993006993005
935,company forest,2.9206776556776557
936,ads,2.9092198581560282
937,differ materially,2.888888888888889
938,liquidity,2.8598930481283427
939,company,2.847264957264957
940,reimbursement,2.821937321937322
941,indication,2.775
942,uncertainty,2.75
943,disease parkinson,2.7254249815225426
944,observable,2.7142857142857144
945,guidance change,2.7131147540983607
946,ads,2.709219858156028
947,company doe,2.667972027972028
948,merz,2.6666666666666665
949,tax,2.625
950,january ads,2.621500559910414
951,data,2.6097560975609757
952,equity,2.6
953,trial,2.5964912280701755
954,fair presentation,2.5721153846153846
955,organization,2.5652173913043477
956,beginning,2.527027027027027
957,cash,2.525
958,significant,2.5180722891566263
959,award,2.5
960,clinical,2.4954954954954953
961,related,2.490322580645161
962,month,2.4662162162162162
963,issued,2.4603174603174605
964,adoption,2.45
965,early,2.4444444444444446
966,raised,2.423076923076923
967,stock,2.4177631578947367
968,pursuant,2.4166666666666665
969,financial,2.3865546218487395
970,approximately,2.3823529411764706
971,requires,2.375
972,statement,2.369047619047619
973,accounting,2.3684210526315788
974,adamas,2.3636363636363638
975,september,2.35
976,interim,2.3461538461538463
977,sufficient,2.3333333333333335
978,expense,2.3043478260869565
979,annual,2.3043478260869565
980,interest,2.3043478260869565
981,potentially,2.2857142857142856
982,filer,2.2777777777777777
983,directors,2.25
984,recognition,2.25
985,lawsuit,2.25
986,public,2.25
987,valuation,2.25
988,market,2.2459016393442623
989,awarded,2.230769230769231
990,received,2.2266666666666666
991,approval,2.2
992,court,2.2
993,based,2.1880341880341883
994,offering,2.1847826086956523
995,common,2.1818181818181817
996,basis,2.1818181818181817
997,revenue,2.173611111111111
998,security,2.1724137931034484
999,drug,2.171875
1000,capital,2.1666666666666665
1001,levodopa,2.1538461538461537
1002,sec,2.1538461538461537
1003,asu,2.142857142857143
1004,dyskinesia,2.142857142857143
1005,reported,2.1315789473684212
1006,include,2.129032258064516
1007,mid,2.125
1008,included,2.1153846153846154
1009,judgment,2.108108108108108
1010,discount,2.108108108108108
1011,future,2.1058823529411765
1012,year,2.103448275862069
1013,study,2.0952380952380953
1014,selling,2.0869565217391304
1015,milestone,2.0833333333333335
1016,fda,2.081081081081081
1017,fee,2.0789473684210527
1018,stage,2.076923076923077
1019,input,2.074626865671642
1020,royalty,2.0642201834862384
1021,march,2.0602409638554215
1022,loss,2.0602409638554215
1023,product,2.059880239520958
1024,nda,2.0588235294117645
1025,activity,2.025
1026,portfolio,2.0
1027,element,2.0
1028,performed,2.0
1029,site,2.0
1030,preclinical,2.0
1031,manufacturing,2.0
1032,noncurrent,2.0
1033,pricing,2.0
1034,incurred,2.0
1035,summary,2.0
1036,litigation,2.0
1037,exercised,2.0
1038,extension,2.0
1039,commission,2.0
1040,designed,2.0
1041,prior,2.0
1042,success,2.0
1043,degree,2.0
1044,circumstance,2.0
1045,maturity,2.0
1046,seeking,2.0
1047,ucb,2.0
1048,issue,2.0
1049,tolerability,2.0
1050,account,2.0
1051,presented,2.0
1052,repayment,2.0
1053,prepayment,2.0
1054,vimpat,2.0
1055,number,1.9743589743589745
1056,total,1.9666666666666666
1057,arrangement,1.9649122807017543
1058,loan,1.9642857142857142
1059,entity,1.9583333333333333
1060,license,1.952054794520548
1061,filed,1.9473684210526316
1062,term,1.945054945054945
1063,therapeutic,1.9411764705882353
1064,information,1.9375
1065,lesser,1.9375
1066,development,1.9350649350649352
1067,declared,1.9285714285714286
1068,considered,1.9166666666666667
1069,purchase,1.9142857142857144
1070,sell,1.903225806451613
1071,agreement,1.9022222222222223
1072,plan,1.8902439024390243
1073,fund,1.8846153846153846
1074,patent,1.8823529411764706
1075,gain,1.8823529411764706
1076,business,1.875
1077,impairment,1.875
1078,warrant,1.8709677419354838
1079,receive,1.8695652173913044
1080,exchange,1.8666666666666667
1081,decrease,1.8666666666666667
1082,level,1.8658536585365855
1083,subject,1.8571428571428572
1084,active,1.8571428571428572
1085,provide,1.8571428571428572
1086,june,1.8503937007874016
1087,contract,1.847457627118644
1088,disclosure,1.8461538461538463
1089,effective,1.8448275862068966
1090,component,1.8421052631578947
1091,licensed,1.8421052631578947
1092,district,1.8421052631578947
1093,normal,1.8333333333333333
1094,compared,1.8333333333333333
1095,method,1.8333333333333333
1096,approach,1.8333333333333333
1097,management,1.8214285714285714
1098,property,1.8095238095238095
1099,claim,1.8076923076923077
1100,period,1.8012048192771084
1101,earlier,1.8
1102,vote,1.8
1103,platform,1.8
1104,cowen,1.8
1105,asset,1.7934782608695652
1106,amount,1.7922077922077921
1107,research,1.7909604519774012
1108,general,1.7843137254901962
1109,date,1.7841726618705036
1110,achieve,1.7777777777777777
1111,action,1.7777777777777777
1112,lacosamide,1.7777777777777777
1113,approved,1.7735849056603774
1114,grant,1.7727272727272727
1115,andas,1.7692307692307692
1116,symptom,1.7692307692307692
1117,option,1.7640449438202248
1118,identical,1.75
1119,pay,1.75
1120,forward,1.75
1121,consistent,1.75
1122,earned,1.75
1123,pioneered,1.75
1124,cost,1.7472527472527473
1125,contingent,1.7407407407407407
1126,part,1.7407407407407407
1127,make,1.7407407407407407
1128,launch,1.7307692307692308
1129,terminated,1.7272727272727273
1130,vary,1.7142857142857142
1131,aim,1.7142857142857142
1132,vendor,1.7142857142857142
1133,probability,1.7142857142857142
1134,response,1.7142857142857142
1135,performance,1.7058823529411764
1136,achieved,1.7058823529411764
1137,material,1.7
1138,classified,1.7
1139,cantor,1.7
1140,sale,1.6995073891625616
1141,share,1.6963562753036436
1142,investment,1.6956521739130435
1143,rate,1.6923076923076923
1144,derived,1.6875
1145,exercise,1.6730769230769231
1146,service,1.6710526315789473
1147,complication,1.6666666666666667
1148,accrual,1.6666666666666667
1149,good,1.6666666666666667
1150,impact,1.6666666666666667
1151,table,1.6666666666666667
1152,memantine,1.6666666666666667
1153,aggregate,1.6666666666666667
1154,begin,1.6666666666666667
1155,bifurcated,1.6666666666666667
1156,case,1.6666666666666667
1157,timed,1.6666666666666667
1158,rise,1.6666666666666667
1159,condition,1.65
1160,develop,1.6470588235294117
1161,completed,1.6451612903225807
1162,employee,1.6428571428571428
1163,december,1.64
1164,espp,1.6363636363636365
1165,liquidity,1.6363636363636365
1166,reimbursement,1.6296296296296295
1167,rendered,1.625
1168,financing,1.625
1169,issuance,1.625
1170,type,1.625
1171,occurrence,1.625
1172,assumption,1.6176470588235294
1173,bedtime,1.6153846153846154
1174,lease,1.6153846153846154
1175,measurement,1.6153846153846154
1176,premium,1.6153846153846154
1177,completion,1.6153846153846154
1178,daily,1.6111111111111112
1179,thousand,1.607843137254902
1180,full,1.6071428571428572
1181,made,1.605263157894737
1182,party,1.603448275862069
1183,underwriter,1.6
1184,percent,1.6
1185,prosecution,1.5833333333333333
1186,hierarchy,1.5769230769230769
1187,personnel,1.5714285714285714
1188,people,1.5714285714285714
1189,iii,1.5625
1190,materially,1.5555555555555556
1191,lid,1.550561797752809
1192,sold,1.5454545454545454
1193,factor,1.5454545454545454
1194,result,1.5384615384615385
1195,commercialize,1.5333333333333334
1196,disease,1.5303030303030303
1197,namzaric,1.5205479452054795
1198,liability,1.510204081632653
1199,gaap,1.5
1200,generated,1.5
1201,adequate,1.5
1202,adjusted,1.5
1203,fixed,1.5
1204,collectability,1.5
1205,change,1.5
1206,obligation,1.5
1207,defined,1.5
1208,advance,1.5
1209,recorded,1.5
1210,consideration,1.5
1211,allocate,1.5
1212,concern,1.5
1213,estimation,1.5
1214,readily,1.5
1215,accumulated,1.5
1216,charged,1.5
1217,exposure,1.5
1218,expenditure,1.5
1219,incorporation,1.5
1220,limit,1.5
1221,exclusivities,1.5
1222,uncertainty,1.5
1223,seek,1.5
1224,efficacy,1.5
1225,predict,1.5
1226,allocated,1.5
1227,source,1.5
1228,delay,1.5
1229,medicine,1.5
1230,attributable,1.5
1231,initiate,1.5
1232,opposition,1.5
1233,patient,1.4936708860759493
1234,company,1.4861538461538462
1235,includes,1.4814814814814814
1236,million,1.464705882352941
1237,report,1.4642857142857142
1238,allergan,1.463768115942029
1239,director,1.4634146341463414
1240,commercially,1.4545454545454546
1241,manufacture,1.4545454545454546
1242,alternative,1.4545454545454546
1243,forest,1.4345238095238095
1244,portion,1.4285714285714286
1245,standard,1.4230769230769231
1246,conducting,1.4166666666666667
1247,affected,1.411764705882353
1248,defendant,1.411764705882353
1249,increase,1.4090909090909092
1250,commercialization,1.4035087719298245
1251,analysis,1.4
1252,indication,1.4
1253,ads,1.375886524822695
1254,amantadine,1.375
1255,time,1.375
1256,relating,1.375
1257,expiration,1.375
1258,progress,1.375
1259,recognize,1.375
1260,ongoing,1.375
1261,hcrp,1.375
1262,expected,1.372093023255814
1263,life,1.3636363636363635
1264,entered,1.3611111111111112
1265,timing,1.35
1266,initiation,1.3333333333333333
1267,america,1.3333333333333333
1268,resource,1.3333333333333333
1269,reasonable,1.3333333333333333
1270,differ,1.3333333333333333
1271,provided,1.3333333333333333
1272,evaluate,1.3333333333333333
1273,previously,1.3333333333333333
1274,owned,1.3333333333333333
1275,dividend,1.3333333333333333
1276,operations,1.3333333333333333
1277,intend,1.3333333333333333
1278,enter,1.3333333333333333
1279,understanding,1.3333333333333333
1280,characterized,1.3333333333333333
1281,presentation,1.3125
1282,anticipate,1.3125
1283,quarter,1.3076923076923077
1284,collaboration,1.303030303030303
1285,conduct,1.2941176470588236
1286,facility,1.2857142857142858
1287,excluded,1.2777777777777777
1288,epilepsy,1.2777777777777777
1289,determined,1.2727272727272727
1290,amortized,1.2727272727272727
1291,april,1.263157894736842
1292,fair,1.2596153846153846
1293,calculated,1.25
1294,expire,1.25
1295,discussed,1.25
1296,primary,1.25
1297,food,1.25
1298,january,1.2456140350877194
1299,control,1.2307692307692308
1300,estimate,1.223529411764706
1301,amortization,1.2222222222222223
1302,addition,1.2195121951219512
1303,guidance,1.2131147540983607
1304,operation,1.2115384615384615
1305,alzheimer,1.2105263157894737
1306,continue,1.2075471698113207
1307,enhancing,1.2
1308,ipo,1.2
1309,required,1.2
1310,low,1.2
1311,parkinson,1.1951219512195121
1312,expect,1.1923076923076923
1313,update,1.1875
1314,doe,1.1818181818181819
1315,process,1.1818181818181819
1316,notes,1.1666666666666667
1317,july,1.1666666666666667
1318,located,1.1666666666666667
1319,form,1.1666666666666667
1320,substantially,1.1666666666666667
1321,day,1.1666666666666667
1322,carrying,1.1666666666666667
1323,funded,1.1666666666666667
1324,accounted,1.1428571428571428
1325,reduction,1.1428571428571428
1326,met,1.1363636363636365
1327,classification,1.1333333333333333
1328,affect,1.1176470588235294
1329,recognized,1.108695652173913
1330,support,1.105263157894737
1331,treatment,1.1018518518518519
1332,permitted,1.1
1333,results,1.0909090909090908
1334,event,1.0833333333333333
1335,effect,1.0789473684210527
1336,delaware,1.0769230769230769
1337,february,1.0714285714285714
1338,limited,1.0666666666666667
1339,filing,1.0588235294117647
1340,developing,1.0555555555555556
1341,november,1.0333333333333334
1342,create,1.0
1343,intended,1.0
1344,initiated,1.0
1345,larger,1.0
1346,exploring,1.0
1347,utility,1.0
1348,mdx,1.0
1349,follow,1.0
1350,state,1.0
1351,headquarters,1.0
1352,prepared,1.0
1353,accordance,1.0
1354,instruction,1.0
1355,article,1.0
1356,regulation,1.0
1357,read,1.0
1358,conjunction,1.0
1359,securities,1.0
1360,dedicated,1.0
1361,generation,1.0
1362,receives,1.0
1363,satisfy,1.0
1364,entitled,1.0
1365,estimates,1.0
1366,preparation,1.0
1367,conformity,1.0
1368,board,1.0
1369,ratio,1.0
1370,reflect,1.0
1371,criterion,1.0
1372,determinable,1.0
1373,deliverable,1.0
1374,determine,1.0
1375,achievement,1.0
1376,transfer,1.0
1377,participate,1.0
1378,partner,1.0
1379,applying,1.0
1380,entirety,1.0
1381,inception,1.0
1382,passage,1.0
1383,commensurate,1.0
1384,commencement,1.0
1385,behalf,1.0
1386,adjust,1.0
1387,receipt,1.0
1388,scale,1.0
1389,cro,1.0
1390,reviewed,1.0
1391,reasonableness,1.0
1392,match,1.0
1393,point,1.0
1394,capitalized,1.0
1395,expensed,1.0
1396,delivered,1.0
1397,computation,1.0
1398,greater,1.0
1399,estimating,1.0
1400,order,1.0
1401,forfeited,1.0
1402,contracts,1.0
1403,customers,1.0
1404,amendment,1.0
1405,depict,1.0
1406,customer,1.0
1407,reflects,1.0
1408,identify,1.0
1409,replace,1.0
1410,adopt,1.0
1411,selected,1.0
1412,august,1.0
1413,uncertainties,1.0
1414,ability,1.0
1415,responsibility,1.0
1416,evaluating,1.0
1417,offsetting,1.0
1418,apply,1.0
1419,retrospectively,1.0
1420,leases,1.0
1421,provision,1.0
1422,lessee,1.0
1423,exception,1.0
1424,fall,1.0
1425,category,1.0
1426,aspect,1.0
1427,measurements,1.0
1428,disclosures,1.0
1429,establishes,1.0
1430,corroborated,1.0
1431,supported,1.0
1432,measured,1.0
1433,earnings,1.0
1434,reclassified,1.0
1435,accretion,1.0
1436,investments,1.0
1437,maximum,1.0
1438,sublicense,1.0
1439,connection,1.0
1440,moderate,1.0
1441,reimbursable,1.0
1442,reflected,1.0
1443,affiliate,1.0
1444,sublicensees,1.0
1445,respect,1.0
1446,eliminated,1.0
1447,divided,1.0
1448,variety,1.0
1449,representation,1.0
1450,warranty,1.0
1451,unknown,1.0
1452,matter,1.0
1453,probable,1.0
1454,amended,1.0
1455,officer,1.0
1456,serving,1.0
1457,capacity,1.0
1458,enable,1.0
1459,recover,1.0
1460,enforce,1.0
1461,notice,1.0
1462,kgaa,1.0
1463,infringed,1.0
1464,infringement,1.0
1465,enjoined,1.0
1466,importing,1.0
1467,infringe,1.0
1468,induce,1.0
1469,contribute,1.0
1470,series,1.0
1471,indefiniteness,1.0
1472,review,1.0
1473,begun,1.0
1474,scheduled,1.0
1475,october,1.0
1476,ordinary,1.0
1477,presently,1.0
1478,holder,1.0
1479,class,1.0
1480,priority,1.0
1481,vested,1.0
1482,acting,1.0
1483,vest,1.0
1484,anniversary,1.0
1485,rule,1.0
1486,summarized,1.0
1487,continuing,1.0
1488,discussion,1.0
1489,section,1.0
1490,intention,1.0
1491,twofold,1.0
1492,improve,1.0
1493,submit,1.0
1494,combination,1.0
1495,possibly,1.0
1496,assure,1.0
1497,unable,1.0
1498,remain,1.0
1499,continuation,1.0
1500,administer,1.0
1501,discovery,1.0
1502,cros,1.0
1503,monitoring,1.0
1504,acquiring,1.0
1505,production,1.0
1506,compliance,1.0
1507,reallocated,1.0
1508,costly,1.0
1509,crucial,1.0
1510,quality,1.0
1511,past,1.0
1512,situation,1.0
1513,largely,1.0
1514,forecast,1.0
1515,certainty,1.0
1516,duration,1.0
1517,extent,1.0
1518,disclosed,1.0
1519,profit,1.0
1520,difficult,1.0
1521,decide,1.0
1522,scope,1.0
1523,put,1.0
1524,hold,1.0
1525,engaged,1.0
1526,clarify,1.0
1527,governed,1.0
1528,invalidity,1.0
1529,appeal,1.0
1530,appeals,1.0
1531,heard,1.0
1532,settled,1.0
1533,varied,1.0
1534,conclusion,1.0
1535,anticipation,1.0
1536,marketing,1.0
1537,europe,1.0
1538,offsetexpenses,1.0
1539,methodology,1.0
1540,eligible,1.0
1541,administered,1.0
1542,conducted,1.0
1543,establish,1.0
1544,deadline,1.0
1545,marketed,1.0
1546,improvements,1.0
1547,termination,1.0
1548,step,1.0
1549,unpredictable,1.0
1550,goal,1.0
1551,contemplated,1.0
1552,inconsequential,1.0
1553,track,1.0
1554,nominated,1.0
1555,increasingly,1.0
1556,high,1.0
1557,uncertain,1.0
1558,patients,1.0
1559,execute,1.0
1560,deployment,1.0
1561,determining,1.0
1562,default,1.0
1563,borrowing,1.0
